Resources
The National Pharmaceutical Council (NPC) is a health policy research organization dedicated to the advancement of good evidence and science, and to fostering an environment in the United States that supports medical innovation.
Filter by:
Topic
Resource Type
Audience
Audience
Display Only
Showing 174 Results
New Research Demonstrates Disproportionate Access to Specialty Drugs by Wage and Race
A review of employer-sponsored health plan data found that non-white and low-wage workers may struggle to access specialty medicines for autoimmune diseases.
New Research Finds Patient Access to Drugs Selected for IRA Is Often High (JAMA Health Forum)
A review of Medicare Part D coverage for 10 drugs in the Medicare Drug Price Negotiation Program raises concerns about how program implementation may impact patient access.
NPC Releases Updated Guiding Practices to Improve Patient-Centricity in Value Assessments
The Guiding Practices include 33 specific recommendations to ensure value assessments account for the full value pharmaceuticals provide to patients and society
Global Experts Highlight Concerns With Implementation of IRA-Mandated Medicare Drug Price Negotiation Program
Value in Health highlights commentary contributed by NPC's John O'Brien and NPC board member Jan E. Hansen on the implications of the Medicare Drug Price Negotiation Program.
New Analysis Shows IRA May Lead to Delayed Launches, Fewer Subsequent Indications, and Less Evidence Generation
NPC writes in Health Affairs Forefront about the unintended consequences of the IRA and the impact of the changing economic incentives for clinical development programs.
Why It Is Critical to Include Dynamic Drug Pricing in Cost-Effectiveness Analysis in a Post-IRA World
The drug price-related provisions of the Inflation Reduction Act make the case for including dynamic drug pricing in cost-effectiveness analysis even more compelling.
New Research Finds Commercial Health Plans' Use of Prescriber Requirements Doubled and Use of Step Therapy Increased by More Than 31% for Specialty Drug Coverage
New research co-authored by NPC examines how health plan policies have become more restrictive over time.
National Pharmaceutical Council Adds Executive Leaders, Names Dr. Jon Campbell as Chief Science Officer
Michael Pratt named Chief Communications Officer as NPC boosts research and engagement capabilities
E.V.I.dently® | August 2022
In this issue: Evidence and drug pricing policy, wages and access to care, the (minimal) costs of expanding pre-deductible coverage.
E.V.I.dently® | May 2022
In this issue: Improving benefit design, patient perspectives on innovation, resources to guide health spending research and policy-making & more.
2021 Annual Report
In 2021, NPC conducted policy-relevant research and analysis to foster evidence-based health policy discussions and decision-making. Learn more in our Annual Report.
E.V.I.dently® | March 2022
In this issue: Measuring the impact of innovation, new resources to navigate health spending research and policy-making, good practices for HDHPs and a busy spring event calendar.
Employers Identify Best Practices for High-Deductible Health Plans in New Research From the National Pharmaceutical Council and Gallagher Research & Insights
Webinar highlights new research and steps employers can take to implement better HDHP designs.
E.V.I.dently® | January 2022
In this issue: We offer a new resource on the myth of the "average" patient, outline key challenges in value assessment and health technology assessment, and highlight two upcoming webinars.
National Pharmaceutical Council Appoints Dr. Sharon Phares as Chief Scientific Officer
NPC announced the appointment of Sharon Phares, PhD, MPH, as Chief Scientific Officer.
E.V.I.dently® | November 2021
In this issue: Explore the pitfalls in the most recent drug pricing deal, regulation that's led to improvements in employee benefits and keys to improving equity in health coverage.